Bloomberg BNA’s Corporate Law & Accountability Report is available on the Corporate Law Resource Center. This news service keeps corporate practitioners informed of legal developments of...
By Che Odom
June 4 — Current trends suggest that shareholder activism will increase, so it is in a company's interest to develop effective ways of responding, including the use of the maligned poison pill and exclusive-forum bylaw provisions.
That advice comes from Keir D. Gumbs, a partner at Covington & Burling LLP in Washington, DC, who spoke June 4 during an InsideCounsel webinar, “2014 Proxy Season Wrap Up,” which was sponsored by Bloomberg BNA.
“You should regularly look at your structural defenses,” Gumbs, who advises clients on corporate governance, securities regulation and transactional matters, said. “Think about things that you can do that may not be what ISS or some of the larger governance-related institution investors would like but would nonetheless be in the best interests of your shareholders.”
Gumbs presented the webinar with Lillian Brown, a partner at Wilmer Cutler Pickering Hale and Dorr LLP, who focuses her practice on federal securities law compliance and corporate governance matters. They discussed shareholder proposals, judicial decisions involving shareholders litigation and tips for the 2015 proxy season.
Activist shareholders were very busy and successful in 2013, Brown said. Of the 367 known activist campaigns last year, 90 involved proxy contests, she said. Sixty percent of the activist campaigns in 2013 resulted in settlements or victories for the activists, compared to 36 percent in 2003, she said.
Bill Ackman of Pershing Square Capital Management Inc. is among the busiest hedge-fund managers, Brown said. This week, Bloomberg reported that Ackman called for a special shareholder meeting to remove most of Allergan Inc.'s board to push forward a proposed acquisition by Valeant Pharmaceuticals International Inc.
Activist funds, such as Pershing, outperformed other hedge funds in 2013, though not the S&P 500, according to data provided by Brown. Activist hedge funds averaged returns of approximately 16 percent, compared to 8 percent for other hedge funds, she said.
Given that success, more funds may be tempted to try an activist strategy, she said.
Hedge funds, of course, are not the only activists out there, Brown said. Activists also include institutional investors, such as pension funds, labor unions and environmental groups, and individual “gadflies,” such as John Chevedden, who filed nearly 60 proposals in proxy statements last year.
“You really are looking at very different types of investors when you use the term activist investor,” Brown said, adding activists are motivated by a variety of reasons, such as financial, environment or social issues.
Walden Asset Management, Carl Icahn of Icahn Enterprises, the California State Teachers Retirement System and the AFL-CIO are among the most well-known activists, she said.
Structural defenses may draw the ire of Institutional Shareholder Services Inc., Glass, Lewis & Co. and activists, but companies must consider using them because they can be an effective means of protecting against unwanted takeover bids, Gumbs said.
According to Gumbs, such defenses include:
The number of companies with a poison pill are in the minority, “but I think that number is misleading because they may have one on the shelf that they are ready to adopt in the event there is a real threat,” Gumbs said.
Prevention, in the form of year-round shareholder engagement, can serve as an effective defense against activist campaigns, Brown said.
Directors and officers should identify their significant shareholders and engage them to learn about their concerns, she said.
“Engage on it constructively rather than wait for proxy season to find out and try to defend it,” she said.
Some strategies to consider, according to Brown, are:
Thoughtful, proactive engagement should be done “early and often” and continuously, with the goal of creating relationships in which shareholders reach out to the company, she said.
To contact the reporter on this story: Che Odom in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Jesse Travis at email@example.com
The InsideCounsel webinar is archived and available at http://www.insidecounsel.com/webseminars/2014-proxy-season-wrap-up.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)